Differential genomic and proteomic profiling of glioblastoma cells exposed to terpyridineplatinum(II) complexes

Free Radical Biology and Medicine

Volumn 46, Issue 8, 2009, Pages 1096-1108

  Koncarevic, Sasa ^a,b   Urig, Sabine ^a   Steiner, Klaus ^c   Rahlfs, Stefan ^a   Herold Mende, Christel ^d   Sueltmann, Holger ^c   Becker, Katja ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Proteome Sciences R and D GmbH and Co KG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Free radicals; Glioblastoma; Microarray; Platinum complexes; Proteomics; Thioredoxin reductase

Indexed keywords

2 MERCAPTOPYRIDINE (4' CHLORO 2,2':6',2'' TERPYRIDINE)PLATINUM NITRATE; 4 MERCAPTOPYRIDINE (4' CHLORO 2,2':6',2'' TERPYRIDINE)PLATINUM NITRATE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOSKELETON PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; INITIATION FACTOR 5A; PLATINUM COMPLEX; PROTEIN 14 3 3; PROTEIN P53; PROTEOME; STATHMIN; THIOREDOXIN REDUCTASE; TRANSCRIPTOME; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME INHIBITION; GENETIC TRANSCRIPTION; GENOMICS; GLIOBLASTOMA; HUMAN; HUMAN CELL; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; UPREGULATION;

CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HUMANS; INTERCALATING AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OXIDATION-REDUCTION; PEPTIDE INITIATION FACTORS; PHENOLS; PHOSPHORYLATION; PROTEIN FOLDING; PROTEOME; PYRIDINES; RNA-BINDING PROTEINS; STATHMIN; SULFHYDRYL COMPOUNDS; THIOREDOXIN-DISULFIDE REDUCTASE; TUMOR SUPPRESSOR PROTEIN P53;

RODENTIA;

EID: 63049126568     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.01.013     Document Type: Article

References (70)

1. Mustacich D., and Powis G. Thioredoxin reductase. Biochem. J. 346 (2000) 1-8
2. Tamura T., and Stadtman T.C. Mammalian thioredoxin reductases. Methods Enzymol. 347 (2002) 297-306
3. Becker K., Gromer S., Schirmer R.H., and Muller S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur. J. Biochem. 267 (2000) 6118-6125
4. Gromer S., Urig S., and Becker K. The thioredoxin system-from science to clinic. Med. Res. Rev. 24 (2004) 40-89
5. Yoo M.H., Xu X.M., Carlson B.A., Gladyshev V.N., and Hatfield D.L. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem. 281 (2006) 13005-13008
6. Anestal K., and Arner E.S. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J. Biol. Chem. 278 (2003) 15966-15972
7. Zhao F., Yan J., Deng S., Lan L., He F., Kuang B., and Zeng H. A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines. Cancer Lett. 236 (2006) 46-53
8. Urig S., and Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin. Cancer Biol. 16 (2006) 452-465
9. Arner E.S., and Holmgren A. The thioredoxin system in cancer. Semin. Cancer Biol. 16 (2006) 420-426
10. Turunen N., Karihtala P., Mantyniemi A., Sormunen R., Holmgren A., Kinnula V.L., and Soini Y. Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma. APMIS 112 (2004) 123-132
11. Seemann S., and Hainaut P. Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity. Oncogene 24 (2005) 3853-3863
12. De Angelis L.M., Burger P.C., Green S.B., and Cairncross H.G. Malignant gliomas: who benefits from adjuvant chemotherapy?. Ann. Neurol. 44 (1998) 691-695
13. Haapasalo H., Kylaniemi M., Paunul N., Kinnula V.L., and Soini Y. Expression of antioxidant enzymes in astrocytic brain tumors. Brain Pathol. 13 (2003) 155-164
14. Galanski M., Arion V.B., Jakupec M.A., and Keppler B.K. Recent developments in the field of tumor-inhibiting metal complexes. Curr. Pharm. Des. 9 (2003) 2078-2089
15. Ahmadi R., Urig S., Hartmann M., Helmke B.M., Koncarevic S., Allenberger B., Kienhoefer C., Neher M., Steiner H.H., Unterberg A., Herold-Mende C., and Becker K. Antiglioma activity of 2,2′:6′,2″-terpyridineplatinum(II) complexes in a rat model-effects on cellular redox metabolism. Free Radic. Biol. Med. 40 (2006) 763-778
16. Becker K., Herold-Mende C., Park J.J., Lowe G., and Schirmer R.H. Human thioredoxin reductase is efficiently inhibited by (2,2′:6′,2″-terpyridine)platinum(II) complexes: possible implications for a novel antitumor strategy. J. Med. Chem. 44 (2001) 2784-2792
17. Ross S.A., Carr C.A., Briet J.W., and Lowe G. Transfer of 4′-chloro-2,2′:6′,2″-terpyridine platinum(II) between human serum albumin, glutathione and other thiolate ligands: a possible selective natural transport mechanism for the delivery of platinum(II) drugs to tumour cells. Anticancer Drug Des. 15 (2000) 431-439
18. Gorg A., Weiss W., and Dunn M.J. Current two-dimensional electrophoresis technology for proteomics. Proteomics 4 (2004) 3665-3685
19. Heukeshoven J., and Dernick R. Improved silver staining procedure for fast staining in PhastSystem Development Unit. I. Staining of sodium dodecyl sulfate gels. Electrophoresis 9 (1988) 28-32
20. Desrivieres S., Kuhn K., Muller J., Glaser M., Laria N.C., Korder J., Sonnentag M., Neumann T., Schwarz J., Schafer J., Hamon C., Groner B., and Prinz T. Comparison of the nuclear proteomes of mammary epithelial cells at different stages of functional differentiation. Proteomics 7 (2007) 2019-2037
21. Van Gelder R.N., von Zastrow M.E., Yool A., Dement W.C., Barchas J.D., and Eberwine J.H. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc. Natl. Acad. Sci. USA 87 (1990) 1663-1667
22. Sambrook J., and Russell D. Molecular Cloning: a Laboratory Manual (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
23. Huber W., von Heydebreck A., Sultmann H., Poustka A., and Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18 Suppl. 1 (2002) S96-104
24. Buness A., Huber W., Steiner K., Sultmann H., and Poustka A. arrayMagic: two-colour cDNA microarray quality control and preprocessing. Bioinformatics 21 (2005) 554-556
25. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 98 (2001) 5116-5121
26. Gromer S., Arscott L.D., Williams Jr. C.H., Schirmer R.H., and Becker K. Human placenta thioredoxin reductase: isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem. 273 (1998) 20096-20101
27. Arscott L.D., Gromer S., Schirmer R.H., Becker K., and Williams Jr. C.H. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli. Proc. Natl. Acad. Sci. USA 94 (1997) 3621-3626
28. Kurdistani S.K., Arizti P., Reimer C.L., Sugrue M.M., Aaronson S.A., and Lee S.W. Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res. 58 (1998) 4439-4444
29. Stein S., Thomas E.K., Herzog B., Westfall M.D., Rocheleau J.V., Jackson II R.S., Wang M., and Liang P. NDRG1 is necessary for p53-dependent apoptosis. J. Biol. Chem. 279 (2004) 48930-48940
30. Tu L.C., Yan X., Hood L., and Lin B. Proteomics analysis of the interactome of N-myc downstream regulated gene 1 and its interactions with the androgen response program in prostate cancer cells. Mol. Cell. Proteomics 6 (2007) 575-588
31. Dong Z., Arnold R.J., Yang Y., Park M.H., Hrncirova P., Mechref Y., Novotny M.V., and Zhang J.T. Modulation of differentiation-related gene 1 expression by cell cycle blocker mimosine, revealed by proteomic analysis. Mol. Cell. Proteomics 4 (2005) 993-1001
32. Hoffman B.D., Hanauske-Abel H.M., Flint A., and Lalande M. A new class of reversible cell cycle inhibitors. Cytometry 12 (1991) 26-32
33. Watson P.A., Hanauske-Abel H.H., Flint A., and Lalande M. Mimosine reversibly arrests cell cycle progression at the G1-S phase border. Cytometry 12 (1991) 242-246
34. Wolff E.C., and Park M.H. Identification of lysine350 of yeast deoxyhypusine synthase as the site of enzyme intermediate formation. Yeast 15 (1999) 43-50
35. Castagna A., Antonioli P., Astner H., Hamdan M., Righetti S.C., Perego P., Zunino F., and Righetti P.G. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 4 (2004) 3246-3267
36. Hermeking H., and Benzinger A. 14-3-3 proteins in cell cycle regulation. Semin. Cancer Biol. 16 (2006) 183-192
37. Rubin C.I., and Atweh G.F. The role of stathmin in the regulation of the cell cycle. J. Cell. Biochem. 93 (2004) 242-250
38. Strey C.W., Spellman D., Stieber A., Gonatas J.O., Wang X., Lambris J.D., and Gonatas N.K. Dysregulation of stathmin, a microtubule-destabilizing protein, and up-regulation of Hsp25, Hsp27, and the antioxidant peroxiredoxin 6 in a mouse model of familial amyotrophic lateral sclerosis. Am. J. Pathol. 165 (2004) 1701-1718
39. Rodriguez O.C., Schaefer A.W., Mandato C.A., Forscher P., Bement W.M., and Waterman-Storer C.M. Conserved microtubule-actin interactions in cell movement and morphogenesis. Nat. Cell Biol. 5 (2003) 599-609
40. Kinoshita K., Arnal I., Desai A., Drechsel D.N., and Hyman A.A. Reconstitution of physiological microtubule dynamics using purified components. Science 294 (2001) 1340-1343
41. Andersen S.S., and Wittmann T. Toward reconstitution of in vivo microtubule dynamics in vitro. Bioessays 24 (2002) 305-307
42. Curmi P.A., Gavet O., Charbaut E., Ozon S., Lachkar-Colmerauer S., Manceau V., Siavoshian S., Maucuer A., and Sobel A. Stathmin and its phosphoprotein family: general properties, biochemical and functional interaction with tubulin. Cell Struct. Funct. 24 (1999) 345-357
43. Smart D.K., Ortiz K.L., Mattson D., Bradbury C.M., Bisht K.S., Sieck L.K., Brechbiel M.W., and Gius D. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res. 64 (2004) 6716-6724
44. Becker K., Ortiz K.L., Park J.J., Lowe G., and Schirmer R.H. Thioredoxin reductase as a novel antitumor strategy. J. Med. Chem. 44 (2001) 2784-2792
45. Rahman-Roblick R., Roblick U.J., Hellman U., Conrotto P., Liu T., Becker S., Hirschberg D., Jornvall H., Auer G., and Wiman K.G. p53 targets identified by protein expression profiling. Proc. Natl. Acad. Sci. USA 104 (2007) 5401-5406
46. Troester M.A., Hoadley K.A., Sorlie T., Herbert B.S., Borresen-Dale A.L., Lonning P.E., Shay J.W., Kaufmann W.K., and Perou C.M. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 64 (2004) 4218-4226
47. Waga S., Hannon G.J., Beach D., and Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369 (1994) 574-578
48. Chuang L.S., Ian H.I., Koh T.W., Ng H.H., Xu G., and Li B.F. Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 277 (1997) 1996-2000
49. Vigneron A., Cherier J., Barre B., Gamelin E., and Coqueret O. The cell cycle inhibitor p21waf1 binds to the myc and cdc25A promoters upon DNA damage and induces transcriptional repression. J. Biol. Chem. 281 (2006) 34742-34750
50. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?. Trends Cell Biol. 13 (2003) 65-70
51. Fritah A., Saucier C., Mester J., Redeuilh G., and Sabbah M. p21WAF1/CIP1 selectively controls the transcriptional activity of estrogen receptor alpha. Mol. Cell. Biol. 25 (2005) 2419-2430
52. Perkins N.D. Not just a CDK inhibitor: regulation of transcription by p21(WAF1/CIP1/SDI1). Cell Cycle 1 (2002) 39-41
53. Ho J.S., Ma W., Mao D.Y., and Benchimol S. p53-dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol. Cell. Biol. 25 (2005) 7423-7431
54. Li J., and Kretzner L. The growth-inhibitory Ndrg1 gene is a Myc negative target in human neuroblastomas and other cell types with overexpressed N- or c-myc. Mol. Cell. Biochem. 250 (2003) 91-105
55. Zhang J., Li F., Liu X., Shen L., Liu J., Su J., Zhang W., Deng Y., Wang L., Liu N., Han W., Ji S., Yang A., Han H., and Yao L. The repression of human differentiation-related gene NDRG2 expression by Myc via Miz-1-dependent interaction with the NDRG2 core promoter. J. Biol. Chem. 281 (2006) 39159-39168
56. Chatterjee I., Gross S.R., Kinzy T.G., and Chen K.Y. Rapid depletion of mutant eukaryotic initiation factor 5A at restrictive temperature reveals connections to actin cytoskeleton and cell cycle progression. Mol. Genet. Genomics 275 (2006) 264-276
57. Huo J.X., Metz S.A., and Li G.D. p53-independent induction of p21(waf1/cip1) contributes to the activation of caspases in GTP-depletion-induced apoptosis of insulin-secreting cells. Cell Death Differ. 11 (2004) 99-109
58. Alpan R.S., and Pardee A.B. p21WAF1/CIP1/SDI1 is elevated through a p53-independent pathway by mimosine. Cell Growth Differ. 7 (1996) 893-901
59. Hsieh S.Y., Zhuang F.H., Wu Y.T., Chen J.K., and Lee Y.L. Profiling the proteome dynamics during the cell cycle of human hepatoma cells. Proteomics 8 (2008) 2872-2884
60. Boyce M., and Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ. 13 (2006) 363-373
61. Schroder M., and Kaufman R.J. The mammalian unfolded protein response. Annu. Rev. Biochem. 74 (2005) 739-789
62. Niethammer P., Kronja I., Kandels-Lewis S., Rybina S., Bastiaens P., and Karsenti E. Discrete states of a protein interaction network govern interphase and mitotic microtubule dynamics. PLoS Biol. 5 (2007) e29
63. Jennette K.W., Lippard S.J., Vassiliades G.A., and Bauer W.R. Metallointercalation reagents: 2-hydroxyethanethiolato(2,2′,2′-terpyridine)-platinum(II) monocation binds strongly to DNA by intercalation. Proc. Natl. Acad. Sci. USA 71 (1974) 3839-3843
64. Wang D., and Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discovery 4 (2005) 307-320
65. Rabik C.A., and Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33 (2007) 9-23
66. Lowe G., Droz A.S., Vilaivan T., Weaver G.W., Park J.J., Pratt J.M., Tweedale L., and Kelland L.R. Cytotoxicity of 2,2′:6′,2″-terpyridineplatinum(II) complexes against human ovarian carcinoma. J. Med. Chem. 42 (1999) 3167-3174
67. Arner E.S., Nakamura H., Sasada T., Yodoi J., Holmgren A., and Spyrou G. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic. Biol. Med. 31 (2001) 1170-1178
68. Witte A.B., Anestal K., Jerremalm E., Ehrsson H., and Arner E.S. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic. Biol. Med. 39 (2005) 696-703
69. Urig S., Ahmadi R., Herold-Mende C., Alber D., and Becker K. Platinum(II) complexes: inhibition of thioredoxin reductase in glioblastoma therapy. In: Nishino T., Miura R., Tanokura M., and Fukui K. (Eds). Flavins and Flavoproteins (2005), ARchiTect, Tokyo 877-882
70. +) influenced by copper homeostasis. Biochem. Pharmacol. 73 (2007) 1270-1279